Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $343.7 million.

  • Fate Therapeutics' Liabilities and Shareholders Equity fell 3056.73% to $343.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year decrease of 2596.46%. This contributed to the annual value of $440.7 million for FY2024, which is 1294.37% down from last year.
  • Per Fate Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $343.7 million for Q3 2025, which was down 3056.73% from $371.6 million recorded in Q2 2025.
  • Fate Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $1.0 billion during Q1 2021, with a 5-year trough of $343.7 million in Q3 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $584.8 million (2023), whereas its average is $658.0 million.
  • As far as peak fluctuations go, Fate Therapeutics' Liabilities and Shareholders Equity surged by 22494.45% in 2021, and later plummeted by 3056.73% in 2025.
  • Fate Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $921.5 million in 2021, then fell by 23.43% to $705.6 million in 2022, then dropped by 28.25% to $506.2 million in 2023, then fell by 12.94% to $440.7 million in 2024, then dropped by 22.02% to $343.7 million in 2025.
  • Its last three reported values are $343.7 million in Q3 2025, $371.6 million for Q2 2025, and $398.7 million during Q1 2025.